Insulin glargine metabolite 21A-Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: Results from the PRESCHOOL study

Pediatric Diabetes

Volumn 16, Issue 4, 2015, Pages 299-304

  Danne, Thomas ^a   Becker, Reinhard Ha ^b   Ping, Lin ^c   Philotheou, Areti ^d  

^a Centre for Children and Adolescents   (Germany)

^b Sanofi   (Germany)

^c SANOFI   (France)

^d Groote Schuur Hospital and UCT Private Academic Hospital   (South Africa)

Author keywords

Children; Glargine metabolism; Metabolite M1; Pharmacokinetic; Type 1 diabetes

Indexed keywords

21A GLY HUMAN INSULIN; DRUG METABOLITE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; CHILD; CHILDHOOD DISEASE; CONCENTRATION AT STEADY-STATE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TANDEM MASS SPECTROMETRY; TREATMENT DURATION; BLOOD; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 1; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE;

EID: 84928824640     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12161     Document Type: Article

References (21)

1. Evertsen J, Alemzadeh R, Wang X. Increasing incidence of pediatric type 1 diabetes mellitus in Southeastern Wisconsin: relationship with body weight at diagnosis. PLoS One 2009: 4: e6873.
2. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997: 20: 22-25.
3. Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2, 873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care 1997: 20: 714-720.
4. Bangstad HJ, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009: 10 (Suppl. 12): 82-99.
5. European Medicines Agency. Authorisation Lantus Insulin Glargine. 2000. (available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000284/human_med_000882.jsp&mid=WC0b01ac058001d124). Accessed July 25, 2013.
6. Danne T, Philotheou A, Goldman D, et al. A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes 2013: 14: 593-601. doi: 10.1111/pedi.12051 [Epub ahead of print].
7. Salemyr J, Bang P, Ortqvist E. Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study. Pediatr Diabetes 2011: 12: 501-505.
8. Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005: 115: 1320-1324.
9. Monti LD, Poma R, Caumo A et al. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metabolism 1992: 41: 540-544.
10. Steiner DF. Adventures with insulin in the islets of Langerhans. J Biol Chem 2011: 286: 17399-17421.
11. Sommerfeld MR, Muller G, Tschank G et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One 2010: 5: e9540.
12. Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003: 19: 34-40.
13. Lucidi P, Porcellati F, Rossetti P et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care 2011: 34: 1312-1314.
14. Bolli GB, Hahn A, Schmidt R et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supra-therapeutic doses of glargine in subjects with type 1 diabetes mellitus. Diabetes Care 2012: 35: 2626-2630.
15. Hess C, Thomas A, Thevis M et al. Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. Anal Bioanal Chem 2012: 404: 1813-1822.
16. Tennagels N, Werner U. The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem 2013: 119: 1-14.
17. Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014. doi: 10.1111/dom.12283. [Epub ahead of print].
18. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012: 367: 319-328.
19. Blin P, Lassalle R, Dureau-Pournin C et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 2012: 55: 644-653.
20. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases. Diabetes Care 2013: 36: 294-301.
21. Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One 2012: 7: e51814.